Physician profile
Susan Schaffer
NPI 1518997147
$593.30
in general payments reported to CMS, 2019-2025
18 companies · $96.38 in 2025
The $96.38 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.84 · 2021: $23.74 · 2022: $26.22 · 2023: $391 · 2025: $96.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.43 | 2023 | |
| Caris Mpi, INC. | $80.44 | 2025 | Mi Cancer Seek |
| Seagen INC. | $72.52 | 2019-2023 | Padcev |
| Beigene USA, INC. | $68.22 | 2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $39.78 | 2023-2025 | Lynparza, Enhertu |
| Eisai INC. | $24.93 | 2023 | |
| Incyte Corporation | $24.63 | 2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $24.20 | 2023 | Imbruvica |
| Astellas Pharma US INC | $24.08 | 2023 | Xospata |
| Abbvie INC. | $22.92 | 2023 | Venclexta |
| Array Biopharma INC | $20.15 | 2023 | Lorbrena, Mektovi, Braftovi |
| Regeneron Healthcare Solutions, INC. | $19.23 | 2023 | Libtayo |
| G1 Therapeutics, INC. | $16.91 | 2023 | Cosela |
| Pfizer INC. | $16.37 | 2019 | |
| Genentech USA, INC. | $14.89 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2023 | Opdivo |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.